参考文献/References:
[1] CORTINI M,AVNET S,BALDINI N.Mesenchymal stroma: Role in osteosarcoma progression [J].Cancer Lett,2017,405: 90-99.
[2] ROSEN G,MARCOVE R C,CAPARROS B,et al.Primary osteogenic sarcoma: the rationale for preoperative chemothe-rapy and delayed surgery [J].Cancer,1979,43(6): 2163-2177.
[3] GORLICK R,JANEWAY K,LESSNICK S,et al.Children's Oncology Group's 2013 blueprint for research: bone tumors [J].Pediatr Blood Cancer,2013,60(6): 1009-1015.
[4] HILL M,TRAN N.miRNA interplay: mechanisms and con-sequences in cancer [J].Dis Model Mech,2021,14(4): dmm047662.
[5] SALIMINEJAD K,KHORRAM KHORSHID H R,SOLEYMANI FARD S,et al.An overview of microRNAs: biology,functions,therapeutics,and analysis methods [J].J Cell Physiol,2019,234(5): 5451-5465.
[6] ANDERSEN G B,KNUDSEN A,HAGER H,et al.miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts [J].Mol Oncol,2018,12(1): 114-131.
[7] CHANG Y H,HUANG Y L,TSAI H C,et al.Chemokine ligand 2 promotes migration in osteosarcoma by regulating the miR-3659/ MMP-3 Axis [J].Biomedicines,2023,11(10):2768.
[8] ZHENG C,LI R,ZHENG S,et al.The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis [J].Cancer Sci,2023,114(12):4747-4762.
[9] SAADH M J,RASHED A B,JAMAL A,et al.miR-199a-3p suppresses neuroinflammation by directly targeting MyD88 in a mouse model of bone cancer pain [J].Life Sci,2023,333: 122139.
[10] ZHANG D,LIU X,LI Y,et al.LINC01189-miR-586-ZEB1 feedback loop regulates breast cancer progression through Wnt/beta-catenin signaling pathway [J].Mol Ther Nucleic Acids,2021,25: 455-467.
[11] LIU C,YANG J,ZHU F,et al.Exosomal circ_0001190 regulates the progression of gastric cancer via miR-586/SOSTDC1 axis [J].Biochem Genet,2022,60(6): 1895-1913.
[12] LUO Y,HOU W T,ZENG L,et al.Progress in the study of markers related to glioma prognosis [J].Eur Rev Med Pharmacol Sci,2020,24(14): 7690-7697.
[13] MOHAPATRA P,MADHULIKA S,BEHERA S,et al.Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/β-catenin signaling axis [J].Mol Ther Nucleic Acids,2023,34: 102031.
[14] BAHARUDIN R,TIENG F Y F,LEE L H,et al.Epigenetics of SFRP1: the dual roles in human cancers[J].Cancers(Basel),2020,12(2): 445.
[15] ATSCHEKZEI F,HENNENLOTTER J,JANISCH S,et al.SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence[J].Epigenetics,2012,7(5): 447-457.
[16] HENG L,JIA Z,BAI J,et al.Molecular characterization of metastatic osteosarcoma: differentially expressed genes,transcription factors and microRNAs [J].Mol Med Rep,2017,15(5): 2829-2836.
[17] ALESSANDRINI L,MANCHI M,DE RE V,et al.Proposed molecular and miRNA classification of gastric cancer [J].Int J Mol Sci,2018,19(6): 1683.
[18] SABIT H,CEVIK E,TOMBULOGLU H,et al.Triple negative breast cancer in the era of miRNA [J].Crit Rev Oncol Hematol,2021,157: 103196.
[19] GHAFOURI-FARD S,HONARMAND TAMIZKAR K,HUSSEN B M,et al.MicroRNA signature in liver cancer [J].Pathol Res Pract,2021,219: 153369.
[20] 袁长深,容伟明,卢智贤,等.基于生物信息学构建骨肉瘤miRNA-mRNA的调控网络[J].中国组织工程研究,2021,25(17): 2740-2746.
相似文献/References:
[1]许扬梅 龚福生 刘沁颖 刘施佳 黄丽洁 郑秋红.MiR-194过表达和抑制表达对肝癌细胞株Hep-3b中侧群细胞增殖的影响[J].福建医药杂志,2019,41(06):141.
XU Yangmei,GONG Fusheng,LIU Qinying,et al.Influence of miR-194 up and down-expression on liver cancer stem cells[J].FUJIAN MEDICAL JOURNAL,2019,41(01):141.
[2]林文韬 王武炼 肖莉莉 张怡元.基于GEO数据库发现骨肉瘤关键基因GMFG及其生物学功能[J].福建医药杂志,2020,42(02):112.
LIN Wentao,WANG Wulian,XIAO Lili,et al.Identification of the key gene GMFG and its biological function in osteosarcoma based on GEO database[J].FUJIAN MEDICAL JOURNAL,2020,42(01):112.
[3]肖莉莉 刘 晖 贾春锋.基于核酸适配体的微流控芯片的构建及对循环肿瘤细胞筛选性能的测定[J].福建医药杂志,2020,42(02):119.
[4]陈康尧,顾恩毅,蔡碰德,等.H1受体拮抗剂异丙嗪对顺铂治疗骨肉瘤的影响及机制[J].福建医药杂志,2021,43(04):132.
CHEN Kangyao,GU Enyi,CAI Pengde,et al.Efficacy and mechanism of H1 receptor antagonist promethazine on osteosarcoma treated with cisplatin[J].FUJIAN MEDICAL JOURNAL,2021,43(01):132.
[5]钟志辉,林焱斌,庄 研,等.骨肉瘤组织ACTN4和CD133的表达及其影响因素[J].福建医药杂志,2021,43(05):117.
ZHONG Zhihui,LIN Yanbin,ZHUANG Yan,et al.Expression and interfering factors of ACTN4 and CD133 in osteosarcoma[J].FUJIAN MEDICAL JOURNAL,2021,43(01):117.
[6]林东泽.shRNA沉默c-myc基因对MG-63骨肉瘤细胞c-myc/PD-L1轴的影响[J].福建医药杂志,2022,44(05):133.